• The effectiveness of clarithromycin during the acute respiratory diseases in children
To content

The effectiveness of clarithromycin during the acute respiratory diseases in children


The effectiveness of clarithromycin during the acute respiratory diseases in children

Agafonova E. A., Deyev V. V., Moskalenko L. M., Tatyanenko O. V., Titarenko O. V., Kuprinenko N. I., Novikova E. Yu.

State institution «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine»

Communal institution «Dnipropetrovsk City Clinical Hospital №9» of the Dnipropetrovsk regional council, Levoberezhnaya

Centralized Bacteriological Laboratory


Objective: To analyze the clinical efficacy of clarithromycin during the acute respiratory diseases in children with different levels of resistance to bacterial agents.

Patients and methods. The study of eradication and clinical efficacy of clarithromycin in 128 children with clinical manifestations of acute respiratory infections depending on the frequency of incidence during the year is conducted. The main group consisted of 72 (4 or more incidence of ARI per year), control group (3 or less incidence of ARI per year) — 56 children. Clarithromycin was prescribed by a course of 5 days. Etiological diagnosis and sensitivity of pathogens to clarithromycin were determined by means of a culture examination.

The Results. The etiological factor in the main group significantly more was S. aureus OR = 1,49 (CI = 95%; OR = 1,44-1,52) at the same time in 3.7% of children of the first group was marked methicillin-resistant Staphylococcus aureus. Eradication efficacy of clarithromycin in the main group was slightly lower (93.0%) than in the control group (94.6%). However, indicators of clinical efficacy of clarithromycin were higher in the main group, which was manifested by absolute risk reduction in respect of the late positive dynamics of the disease (ARR = 0,21, p> 0,05) and delayed reduction of the leading clinical syndromes (ARR = 0,39, p <0.05).

Conclusions. Clarithromycin can be effectively used as a basic treatment of bacterial acute respiratory infections in children of all ages, especially in children, who often suffer from respiratory diseases.

Key words: clarithromycin, acute respiratory infections, children.



1. Antibiotic treatment in children with sore throat / Linder J. [et. al.] // JAMA. — 2005. — Vol. 294. — P. 2315—2322.

2. Comparison of antimicrobial resistance of nasopharyngeal pneumococci from children from day care centers in European and Asian Russia [abstract C2—937] / Kozlov R. S., Appelbaum P. C., Kosowska K. [et al.]. — 43rd ICAAC. — Chicago, USA, September 14—17, 2003. American Society for Microbiology, 2002. — P. 130.

3. Effects of long-term clarithromycin treatment on lavage fuid markers of infammation in chronic rhinosinusitis / Cervin A., Wallworte B., Mackay-Sim A. [et al.] // Clin. Physiol. Funct. Imaging. — 2009. — Vol. 29. — P. 136—142.

4. Four-year surveillance of antibiotic resistance in Streptococcus pneumoniae in Moscow [abstract 3.31] / Grudinina S. A., Egorov A. M., Zubkov M. M., Sidorenko S. V. // ICMAS-KO 6, Bologna, Italy, January 23–26, 2002.

5. Immunomodulator Clarithromycin Enhances Mucosal and Systemic Immune Responses and Reduces Re-Infection Rate in Pediatric Patientswith Influenza Treated with Antiviral Neuraminidase Inhibitors: A Retrospective Analysis / Shinahara W., Takahashi E., Sawabuchi T. [et al.] // PLoS ONE. — 2013. — Vol. 8 (7).

6. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells / T. Shimizu, S. Shimizu, R. Hattori [et al.] // Am. J. Respir. Crit. Care Med. — 2003. — Vol. 168. — P. 581.

7. Kees F. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers / F. Kees, M. Wellenhofer, H. Grobecker // Infection. — 1995. — Vol. 23. — P. 168—72.

8. Kenealy T. Antibiotics for the common cold and acute purulent rhinitis / T. Kenealy, B. Arroll // Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD000247. DOI: 10.1002/14651858.CD000247.pub3.

9. Labro M. T. Anti_inflammatory activity of macrolides: a new therapeutic potential? / M. T. Labro // Antimicrob Agents Chemother. — 2001. — Vol. 45. — P. 44—47

10. Management of acute otitis media after publication of the 2004 AAP and AAFP clinical practice guideline / Coco A., Vernacchio L., Horst M., Anderson A. // Pediatrics. — 2010. — Vol. 125 (2). — P. 214—20.

11. Nuermberger E. The Clinical Significance of Macrolide-Resistant Streptococcus pneumoniae: It's All Relative / E. Nuermberger,W. R. Bishai // Clin. Infect. Dis. — 2004. — Vol. 38 (1). — P. 93—104.

12. Padilla-Raygoza N. Comparacion entre claritromicina, azitroicina y penicilina en el manejo de la faringitis estreptococica en ninos / N. Padilla Raygoza, M. Moreno-Pacheco // Arch. Inv. Ped. Mex. — 2005. — Vol. 8. — P. 5—11.

13. Periti P. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen / P. Periti, T. Mazzei // J. Chemother. — 1999. — Vol. 11 (1). — P. 11—27.

14. Peters D. H. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potencial / D. H. Peters, S. P. Clissold // Drugs. — 1992. — Vol. 44 (1). — P. 117—64.

15. Tahan F. Clarithromycin in the treatment of RSV bronchitis: a doubleblind, randomized placebo-controlled trial / F. Tahan, A. Ozcan, N. Koc // Eur. Respir. J. — 2007. — Vol. 29. — P. 91—97.

16. The methods of prognostic evaluation of risk of child joining the dispensary group of frequently ill children / Ma?orov R. V., Chereshneva M. V., Verzilin S. D., Chereshnev V. A. // Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. — 2013. — Vol. 5. — P. 12—6. Russian.